In particular, through the FDA accelerated approval process, erdafitinib is indicated to treat metastatic urothelial carcinoma with FGFR2 and FGFR3 alterations, and pemigatinib is indicated to treat unresectable cholangiocarcinoma with fusions or rearrangements of FGFR2 [83]. Here, FGFR2 is linked to cholangiocarcinoma.